UBS (Lux) Equity Fund - Biotech (USD) Q-acc

Register to Unlock Ratings
Performance History31/10/2024
Growth of 1,000 (GBP) Advanced Graph
UBS (Lux) Equity Fund - Biotech (USD) Q-acc
Fund22.0-3.84.3-3.3-2.2
+/-Cat-4.05.312.1-2.0-3.6
+/-B’mrk-10.9-4.11.8-10.6-8.0
 
Key Stats
NAV
20/11/2024
 USD 296.90
Day Change 0.89%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU0400035332
Fund Size (Mil)
20/11/2024
 USD 413.97
Share Class Size (Mil)
20/11/2024
 USD 28.14
Max Initial Charge 5.00%
Ongoing Charge
18/11/2024
  1.10%
Investment Objective: UBS (Lux) Equity Fund - Biotech (USD) Q-acc
The Fund’s investment objective consists in generating strong capital appreciation with a reasonable level of income, while giving due consideration to capital security and the liquidity of the Fund’s assets. UBS Asset Management categorises this sub-fund as an ESG Integration fund that does not promote particular ESG characteristics or pursues a specific sustainability or impact objective. The sub-fund mainly invests in shares and other equity interests of companies focusing on research, product development, product manufacture and distribution in the biotechnology industry and related sectors. The investments can be made in equities and equity interests of large multinationals or other companies whose products are not yet ready for marketing. Investments are made worldwide without restrictions. For the aforementioned reasons, units in this sub-fund may occasionally exhibit substantial price fluctuations.
Returns
Trailing Returns (GBP)20/11/2024
YTD-5.48
3 Years Annualised-1.43
5 Years Annualised2.93
10 Years Annualised5.39
12 Month Yield 0.00
Management
Manager Name
Start Date
Matthew Konosky
01/10/2017
Scott Wilkin
12/07/2024
Click here to see others
Inception Date
12/11/2012
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
MSCI US IMI/BIOTECHNOLOGY 10/40 NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  UBS (Lux) Equity Fund - Biotech (USD) Q-acc31/10/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.760.0098.76
Bond0.000.000.00
Property0.000.000.00
Cash1.500.271.24
Other0.000.000.00
Top 5 Regions%
United States84.29
United Kingdom5.32
Europe - ex Euro5.28
Eurozone5.12
Canada0.00
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare10.09
Alnylam Pharmaceuticals IncHealthcareHealthcare7.33
Neurocrine Biosciences IncHealthcareHealthcare5.12
Moderna IncHealthcareHealthcare4.90
Amgen IncHealthcareHealthcare4.85
UBS (Lux) Equity Fund - Biotech (USD) Q-acc

Related

* This share class has performance data calculated prior to the inception date, 2012-11-12. This is based upon a simulated/extended track record, using the track record of UBS (Lux) EF Biotech (USD) P-acc (ISIN: LU0069152568), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures